Results from study of Portola's factor Xa inhibitor antidote presented at ASH

|About: Portola Pharmaceuticals (PTLA)|By:, SA News Editor

Portola Pharmaceuticals (PTLA +0.1%) says additional results from a Phase 2 study show andexanet alfa immediately reverses the anticoagulation activity of Xarelto.

No SAEs were observed.

Here's PTLA commenting: "Andexanet alfa has the potential to be a first-in-class universal antidote designed to reverse the anticoagulant activity of Factor Xa inhibitors in patients who experience an uncontrolled bleeding episode or who require emergency surgery."

The company estimates as many as 500K patients in the U.S., Japan, and the EU could benefit from such an antidote by 2020. (PR)